Editorial zur Aktualisierung der S2k-Leitlinie Gastrointestinale Infektionen v2.0

Schlüsselwörter

Gastroenteritis - GI-Infektion - Diarrhoe - Campylobacter - Salmonellen - Clostridioides difficile - Flüssigkeitssubstitution - Azithromycin - Fidaxomicin

Publication History

Received: 05 January 2024

Accepted: 08 January 2024

Article published online:
08 July 2024

• Literatur

• 1 Robert Koch Institut (RKI). Infektionsepidemiologisches Jahrbuch für 2020. 2021
• 2 Lammert F, Lynen Jansen P, Lerch MM. Weißbuch Gastroenterologie 2020/2021: De Gruyter. 2019
• 3 Wilking H, Spitznagel H, Werber D. et al. Acute gastrointestinal illness in adults in Germany: a population-based telephone survey. Epidemiol Infect 2013; 141: 2365-2375
• 4 Lübbert C. Gastrointestinale Infektionen: Steigende Hospitalisierungs- und Mortalitätsraten. Deutsches Aerzteblatt 2019;
• 5 Lynen Jansen P, Stallmach A, Lohse AW. et al. [Development of gastrointestinal infectious diseases between 2000 and 2012]. Z Gastroenterol 2014; 52: 549-557
• 6 Axelrad JE, Freedberg DE, Whittier S. et al. Impact of Gastrointestinal Panel Implementation on Health Care Utilization and Outcomes. J Clin Microbiol 2019; 57: e01775-18
• 7 Spina A, Kerr KG, Cormican M. et al. Spectrum of enteropathogens detected by the FilmArray GI Panel in a multicentre study of community-acquired gastroenteritis. Clin Microbiol Infect 2015; 21: 719-728
• 8 Jansen A, Stark K, Kunkel J. et al. Aetiology of community-acquired, acute gastroenteritis in hospitalised adults: a prospective cohort study. BMC Infect Dis 2008; 8: 143
• 9 Spandorfer PR, Alessandrini EA, Joffe MD. et al. Oral versus intravenous rehydration of moderately dehydrated children: a randomized, controlled trial. Pediatrics 2005; 115: 295-301
• 10 Nerandzic MM, Mullane K, Miller MA. et al. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis 2012; 55 (Suppl. 02) S121-S126
• 11 Guery B, Menichetti F, Anttila VJ. et al. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. Lancet Infect Dis 2018; 18: 296-307
• 12 Wilcox MH, Gerding DN, Poxton IR. et al. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. N Engl J Med 2017; 376: 305-317
• 13 Santoiemma PP, Ison MG, Angarone MP. Newer approaches in diagnosis of diarrhea in immunocompromised patients. Curr Opin Infect Dis 2019; 32: 461-467